Results 241 to 250 of about 97,795 (300)

Economic evidence for a watch-and-wait strategy in patients with clinical complete response following neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and a subject-specific critical appraisal

Thapa S, Payne K, Praveen, Malcomson L, Renehan AG.   +4 more
europepmc   +1 more source

Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancer [PDF]

memo - Magazine of European Medical Oncology, 2020
In locally advanced rectal cancer, neoadjuvant chemoradiotherapy provides a significant benefit to local cancer control in addition to total mesorectal excision. However, in 10–40% of all patients, a complete clinical remission can be detected after completion of chemoradiotherapy.
Lunger, Fabian, Peros, Georgios
core   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

[Chemoradiotherapy].

Nihon Geka Gakkai zasshi, 2008
In Western countries, chemotherapy or chemoradiotherapy followed by surgery is the standard treatment and definitive chemoradiotherapy is also standard treatment option for localized advanced esophageal cancer. On the other hand, in Japan, only surgery is recognized as standard of care.
Marcel Verheij, Harry Bartelink
  +5 more sources

Chemoradiotherapy in Gastrointestinal Malignancies

Clinical Oncology, 2009
Over the past 30 years, significant advances have been made in the integration of radiation therapy and chemotherapy in the treatment of patients with localised gastrointestinal malignancies. The therapeutic goal of chemoradiotherapy is to enhance local control resulting in improved survival and outcome of these patients. To define the optimal sequence,
C G, Willett, B G, Czito
openaire   +2 more sources

Rationale for chemoradiotherapy

International Journal of Clinical Oncology, 2004
The rationale for combining chemotherapy (CT) and radiotherapy (RT) is based mainly on two ideas, one being spatial cooperation and the other the enhancement of radiation effects. Spatial cooperation is effective if CT is sufficiently active to eradicate subclinical metastases and if the primary local tumor is effectively treated by RT. In this regard,
openaire   +2 more sources

Chemoradiotherapy in gallbladder cancer

Journal of Surgical Oncology, 2006
AbstractGallbladder cancer (GC) is considered a rare disease associated with a poor prognosis. Unfortunately, the low number of cases makes the performance of trials addressing the role of adjuvant, neoadjuvant, and/or palliative therapy difficult. For a long time, the majority of trials were 5‐fluorouracil (5 FU)‐based, and results were uniformly poor.
Aretxabala, Xabier de, Roa, Juan Carlos, León, Jorge, Maluenda, Fernando, Roa, Iván, Berríos Flores, Marcela Paz, Hepp, Juan, Gallardo, Jorge, Córdova, Andrés   +8 more
openaire   +2 more sources

Adjuvant Chemoradiotherapy and Chemotherapy in Resectable Pancreatic Cancer: A Randomised Controlled Trial

Lancet, The, 2001
Background: The role of adjuvant treatment in pancreatic cancer remains uncertain. The European Study Group for Pancreatic Cancer (ESPAC) assessed the roles of chemoradiotherapy and chemotherapy in a randomised study.
Deborah Stocken, Massimo Falconi, John P Neoptolemos   +2 more
exaly   +2 more sources

Pancreatic cancer chemoradiotherapy

Best Practice & Research Clinical Gastroenterology, 2016
Pancreatic cancer is the most lethal gastrointestinal tumour. Chemotherapy is the mainstay of therapy in the majority of the patients whereas resection is the only chance of cure but only possible in 15-20% of all patients. The integration of radiotherapy into multimodal treatment concepts is heavily investigated.
Brunner, Thomas, Seufferlein, Thomas
openaire   +3 more sources